News

Disclaimer

Disclaimer: MMV accepts no liability for the information presented here or for the consequences of any actions taken on the basis of this information.

1

Photo: PATH

Expert Review Panel for Diagnostics approval expands access to a G6PD deficiency test that supports P. vivax malaria treatment and elimination initiatives

Photo: Marco Corsi/Sigma Tau

New maps could show how to beat malaria

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

New opportunities to prevent P. vivax malaria relapse

A high risk of P. vivax after P. falciparum infection

Photo: Damien Schumann/MMV

Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria

Photo: Fundação de Medicina Tropical

Single-dose tafenoquine for radical cure of P. vivax malaria submitted for regulatory approval in Brazil

Photo: BMC St Jude

Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria

Photo: Maud Lugand/MMV

US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria